Scientists reveal splicing-based mechanism driving therapy resistance in pediatric acute myeloid leukemia

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have improved in recent years, approximately 30% of patients relapse following initial chemotherapy and face poor survival prospects.

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have improved in recent years, approximately 30% of patients relapse following initial chemotherapy and face poor survival prospects.